Global Allergy and Airways Patient Platform (GAAPP) and AstraZeneca launch 'Break Over-Reliance' campaign to help asthma patients break over-reliance on their SABA 'blue' reliever inhaler to prevent asthma attacks

Evidence shows over-reliance on reliever inhalers (use ≥3 times a week) is indicator of increased risk of asthma attacks. Campaign, launching Sept 2020, will provide an evidence-based digital tool (Reliever Reliance Test at to assess reliance on SABA.


Biospace Inc.